Thursday 16 October, 2025
Introduction: Tamoxifen (TAM) is a prodrug established in the treatment of oestrogen receptor-positive breast cancer, yet 25% of patients experience…
Read moreAbstracts
Development of a pharmacokinetic model to predict disposition of Dutasteride in zebrafish embryos
Thursday 16 October, 2025
Objectives: In the last two decades, the zebrafish and especially its embryos gained a lot of interest as animal models…
Read moreUse of Quantitative System Pharmacology (QSP) Modeling to Optimize Dosing Frequency and Interval for Nemvaleukin Alfa (Nemvaleukin), an Investigational Cancer Immunotherapy
Thursday 16 October, 2025
Objectives: Nemvaleukin is a novel engineered protein designed to selectively bind the intermediate-affinity interleukin-2 receptor, preferentially expanding antitumor CD8+ T…
Read moreCovariate Modelling and Bayesian Inference for Physiologically Based Pharmacokinetic Models
Thursday 16 October, 2025
Objectives: We describe a general framework for integrating data on individual-specific covariates (measurable physiological characteristics and other parameters dependent on those)…
Read moreImplementation of Oral Drug Absorption in Older Adults in the Physiologically Based Pharmacokinetic (PBPK) Modelling Platforms
Thursday 16 October, 2025
Objectives: The older population consisting of persons aged 65 years or older is the fastest-growing population group and also the…
Read morePopulation pharmacokinetic analysis of omeprazole according to CYP2C19 polymorphism in elderly subjects
Thursday 16 October, 2025
Objectives: Omeprazole blocks the gastric H+/K+ adenosine triphosphatase, thus inhibiting gastric acid secretion. Omeprazole is extensively metabolized into 5-hydroxy omeprazole…
Read moreElucidating parametric first and second-order effects in PBPK models for special scenarios using a GSA-based approach
Thursday 16 October, 2025
Objectives: Physiological based pharmacokinetic (PBPK) models are convoluted systems with many non-linear or interacting parameters, which can lead to high…
Read morePreclinical pharmacokinetics and target occupancy of JDQ443, a covalent inhibitor targeting KRAS G12C
Thursday 16 October, 2025
Objectives: JDQ443 is an irreversible, covalent KRASG12C inhibitor that is currently being evaluated in clinical trials in patients with non-small…
Read morePopulation pharmacokinetic model to assess bone marrow absorbed dose after 177Lu-Dotatate administration
Thursday 16 October, 2025
Introduction: Lutathera® (177Lu-Dotatate) is a peptide receptor radionuclide therapy indicated in treating gastroenteropancreatic neuroendocrine tumors overexpressing somatostatin receptors. It is…
Read moreA population approach to compare the impact of two amino acid solutions on 177Lu-Dotatate pharmacokinetics in patients with gastroenteropancreatic neuroendocrine tumors
Thursday 16 October, 2025
Introduction: Lutathera® (177Lu-Dotatate) is a peptide receptor radionuclide therapy indicated in the treatment of gastroenteropancreatic neuroendocrine tumors overexpressing somatostatin receptors. It…
Read more